Fig 1: Positive correlations between ADI and soluble ST2 (r = 0.769; p = 0.01) and between SDI and soluble ST2 (r = 0.764; p = 0.01) in sera of IIM patients
Fig 2: Comparison between soluble ST2 concentration in anti-Ro52-positive and anti-Ro52-negative patients as well as anti-SRP-positive and anti-SRP-negative patients
Fig 3: Expression of IL-33 and ST2 in CAFs. (A,B) Expression of IL-33 and ST2 genes/mRNAs in the CAFs in the patient and healthy groups as assessed by qRT-PCR. (C,D) Expression of IL-33 and ST2 genes in the epithelial cells of the patient and healthy groups as assessed by qRT-PCR. (E) Expression of IL-33, ST2, and sST2 protein in the CAFs of the patient and healthy groups as assessed by western blotting. (F) The concentration of IL-33 and sST2 was measured by ELISA assays in the CAFs, healthy, and serum. (G) Expression of IL-33, ST2, and sST2 protein in the epithelial cells of the patient and healthy groups as assessed by western blotting. (H) The concentration of IL-33 and sST2 was measured by ELISA assays in the EPT, healthy, and serum.*p < 0.05 and **p < 0.01.
Fig 4: (A) Acetylation rate at the promoter of IL-33 and ST2 genes in CAFs, EPT, and healthy cells. (B) Immunohistochemical staining of IL-33 and ST2 in the OvC tissue showed the presence of ST2 and IL-33 in both epithelial cells and cancer-associated fibroblasts. (C) Representative image of immunohistochemistry of a-SMA and E-cadherin (in brown) from healthy and tumor samples from OvC patients (objective ×20). Blue arrowheads indicate positive cells in healthy, black arrows heads indicate E-cadherin positive tumor cells, and red arrowheads indicate a-SMA positive stromal cells. (D) Contribution of the IL-33 and T2 protein. (E) Comparison of IL-33 and ST2 genes abundance in tumor epithelial cells and CAFs as determined by qRT-PCR. (F) Comparison of ST2 and IL-33 protein abundance in CAFs and epithelial cells as determined by western blotting. (G) Comparison of ST2 and IL-33 protein concentrations in CAFs and epithelial cells as determined by ELISA. Contribution of the IL-33 and T2 protein. Data are mean ± SEM. *p < 0.02 and **p < 0.01.
Fig 5: Role of ST2 in the induction of COX-2, IL-6, and IL-1ß by IL-33 in CAFs. (A) Effects of ST2 siRNA-mediated knockdown on the protein abundance by IL-33. (B) Effects of siRNA-mediated knockdown of ST2 on the induction of COX-2, IL-6, and IL-1ß and phosphorylation of p38, ERK1/2, JNK, and p65 by IL-33 (100 ng/mL; 1.5 h). *p < 0.05, **p < 0.01, and ***p < 0.001.
Supplier Page from Biorbyt for Human ST2 ELISA Kit
Application Notes: Cell Culture Supernatants, Serum, PlasmaExperiment Notes: Colorimetric